PTC Therapeutics
As of the edition of 20 October 2026, PTC Therapeutics runs 10 drugs, 3 of them marketed; it is on route A at 1 target and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 2 |
| Went quiet | 1 |
| Stopped | 3 |
| Withdrawn from market | 1 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Deflazacort | Ended 2026 (exclusivity) | 0 |
| Sepiapterin | Ends 2038 (patent) | 1 |
| Eladocagene exuparvovec | Ends 2036 (computed from the first US licence) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 1 target.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where PTC Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Inherited and neonatal: 42 trials led
- Nervous system: 31 trials led
- Bones, joints and muscles: 20 trials led